Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne
Comparison of Efficacy of Topical Nadifloxacin With Tretinoin Versus Clindamycin With Tretinoin in Mild-to-Moderate Acne.
The purpose of this randomized controlled trial is to compare the effectiveness of two topical combination treatments for mild-to-moderate acne vulgaris: 1% nadifloxacin with 0.025% tretinoin cream versus 1% clindamycin with 0.025% tretinoin cream. The study will be conducted in the Department of Dermatology, Nishtar Hospital, Multan, and will enroll adults aged 18 to 40 years of either gender who are newly diagnosed with mild-to-moderate acne vulgaris. Participants with drug-induced acne, endocrine disorders (such as PCOS), other chronic facial skin conditions, pregnancy or lactation, chronic systemic illness, or known hypersensitivity to the study medications will be excluded.
Participants will be randomly assigned to one of two groups, with allocation concealed using sealed opaque envelopes. Group A will apply nadifloxacin plus tretinoin cream, and Group B will apply clindamycin plus tretinoin cream. In both groups, a thin layer of the assigned cream will be applied once daily at bedtime to the whole affected area after washing the face with a mild cleanser. Participants will also be advised to use a non-comedogenic moisturizer and sunscreen and to avoid other acne treatments. Follow-up visits will take place at 4, 8, and 12 weeks, with medication use checked by inspecting returned tubes and side effects (redness, dryness, peeling, burning, itching, allergic reactions) recorded at each visit.
At baseline and after 12 weeks of treatment, a consultant dermatologist who is unaware of the treatment assigned will count inflammatory, non-inflammatory, and total lesions and grade acne severity using the Global Acne Grading System. The main outcome is the reduction in the number of inflammatory lesions after 12 weeks. Secondary outcomes are the reduction in non-inflammatory and total lesions, change in acne severity grade, and side effects.
The study hypothesizes that the reduction in inflammatory lesions at 12 weeks is greater with nadifloxacin plus tretinoin than with clindamycin plus tretinoin.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
- Navn: Muhammad T Suleman, MBBS
- Telefonnummer: +92 331 7291061
- E-mail: talha.cascade@gmail.com
Undersøgelse Kontakt Backup
- Navn: Raheel T Associate Professor, FCPS
- Telefonnummer: +92 300 6332846
- E-mail: raheeldermatology1231@gmail.com
Studiesteder
-
-
Punjab Province
-
Multan, Punjab Province, Pakistan, 60000
- Rekruttering
- Nishtar Medical University and Hospital
-
Kontakt:
- Muhammad T Suleman, MBBS
- Telefonnummer: +92 331 7291061
- E-mail: talha.cascade@gmail.com
-
Kontakt:
- Raheel T Associate Professor, FCPS
- Telefonnummer: +92 300 6332846
- E-mail: raheeldermatology1231@gmail.com
-
Ledende efterforsker:
- Muhammad T Suleman, MBBS
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- newly diagnosed with acne vulgaris
- mild to moderate severity
Exclusion Criteria:
- Drug induced acne or acneiform eruptions (corticosteroids, antiepileptics, lithium, iodides)
- endocrine disorders (PCOS, Cushing syndrome, congenital adrenal hyperplasia)
- chronic dermatological conditions affecting face (Rosacea, seborrheic dermatitis, perioral dermatitis)
- pregnant or lactating women
- chronic systemic illness (chronic liver disease, kidney disease)
- patients with known hypersensitivity to study medications
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Nadifloxacin 1% plus Tretinoin 0.025% Cream
After washing the face with a mild cleanser and allowing the skin to dry for 20 to 30 minutes, a thin layer of 1% nadifloxacin combined with 0.025% tretinoin topical cream will be applied once daily at bedtime to the entire acne-affected area, avoiding the eyes, lips, and mucosal surfaces. Participants use a non-comedogenic moisturizer and sunscreen during the day and avoid other topical acne treatments. Treatment continues for 12 weeks |
Topical 1% nadifloxacin cream Topical Tretinoin Cream 0.025% |
|
Aktiv komparator: Clindamycin 1% plus Tretinoin 0.025% Cream
After washing the face with a mild cleanser and allowing the skin to dry for 20 to 30 minutes, a thin layer of 1% clindamycin combined with 0.025% tretinoin topical cream will be applied once daily at bedtime to the entire acne-affected area, avoiding the eyes, lips, and mucosal surfaces. Participants use a non-comedogenic moisturizer and sunscreen during the day and avoid other topical acne treatments. Treatment continues for 12 weeks |
Topical Tretinoin Cream 0.025% Topical Clindamycin 1% cream |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Reduction in number of inflammatory acne lesions
Tidsramme: From randomization to the end of treatment at 12 weeks
|
Change in the number of inflammatory lesions (papules, nodules, pustules), calculated as the difference between the baseline count and the count at 12 weeks. Lesions are counted by a consultant dermatologist blinded to the treatment assigned. |
From randomization to the end of treatment at 12 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Reduction in number of non-inflammatory acne lesions
Tidsramme: From randomization to the end of treatment at 12 weeks
|
Change in the number of non-inflammatory lesions (open and closed comedones), calculated as the difference between the baseline count and the count at 12 weeks, assessed by a blinded consultant dermatologist. |
From randomization to the end of treatment at 12 weeks
|
|
Reduction in total acne lesion count
Tidsramme: From randomization to the end of treatment at 12 weeks
|
Change in the total number of inflammatory and non-inflammatory lesions, calculated as the difference between the baseline count and the count at 12 weeks, assessed by a blinded consultant dermatologist. |
From randomization to the end of treatment at 12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Raheel T Associate Professor, FCPS, Nishtar Medical University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- U1111-1348-8715
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .